Skip to content

Effect of Rocuronium and Sugammadex on Myalgia and Headache After Electro-Convulsive Therapy

Does Rocuronium-sugammadex reduce Myalgia and headache after ECT in patients with major depression?

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000054718
Enrollment
48
Registered
2013-01-16
Start date
2012-02-06
Completion date
2012-07-20
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Abstract Introduction: Myalgia and headache are frequently observed conditions after electroconvulsive therapy (ECT). In this study, we aimed to compare the effects of succinylcholine and rocuronium-sugammadex on myalgia and headache after ECT. Material and Method: Forty five patients undergoing ECT were included in the study. Anesthesia induction was provided with propofol 1 mg/kg and succinylcholine 1 mg/kg in the Group S (n=24), and with propofol 1 mg/kg and rocuronium 0,3 mg/kg in the Group R (n=21). Electroshock was applied after obtaining full muscular relaxation. Sugammadex 4 mg/kg was administered to the group R after the motor seizure. The first three ECT sessions of all the patients were evaluated as regards the time of start of spontaneous respiration following the induction, time of opening the eyes in response to verbal stimuli, and VAS scores for myalgia and headache at hours 2, 6, 12 and 24 following the ECT. Results: There were no significant differences as regards demographic data and hemodynamic data upon comparison of the two groups. The times for the start of the spontaneous respiration and opening the eyes in response to verbal stimuli were found significantly shorter in all the three sessions in the Group R as compared to the Group S (p<0,002). MyalgiaVAS scores at hours 2, 6 and 12 and the headache VAS scores at hours 2 and 6 were significantly higher in the Group S as compared to the Group R (p<0,015). Conclusion: We concluded that the rate of myalgia and headache after ECT was significantly lower in group R than in group S and also the awakening time (spontaneous respiration and opening the eyes in response to verbal stimuli) in group R was significantly shorter than in group S. Key Words: Electroconvulsive therapy, succinylcholine, sugammadex, myalgia, headache

Interventions

Twenty one patients for group R undergoing ECT were included in the study. Anesthesia induction was provided with propofol 1 mg/kg IV and rocuronium 0,3 mg/kg IV in the Group R (n=21). Electroshock was applied after obtaining full muscular relaxation. Sugammadex 4 mg/kg IV was administered to after the motor seizure. Receiving ECT three times a week to complete an average of 6 to 12 treatments. The first three ECT sessions were included in the study. The patients were evaluated as regards the

Twenty one patients for group R undergoing ECT were included in the study. Anesthesia induction was provided with propofol 1 mg/kg IV and rocuronium 0,3 mg/kg IV in the Group R (n=21). Electroshock was applied after obtaining full muscular relaxation. Sugammadex 4 mg/kg IV was administered to after the motor seizure. Receiving ECT three times a week to complete an average of 6 to 12 treatments. The first three ECT sessions were included in the study. The patients were evaluated as regards the time of start of spontaneous respiration following the induction, time of opening the eyes in response to verbal stimuli, and VAS scores for myalgia and headache at hours 2, 6, 12 and 24 following the ECT.

Sponsors

Gaziantep University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Primary purpose
Prevention

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

who would receive ECT three times a week due to major depression, without a history of ECT in the past, between 18-65 years of age, and had a physical status of ASA I and II. Of the 6-12 sessions of ECT, the first three were included in the study.

Exclusion criteria

Patients with neuromuscular, cardio-vascular and renal disease, and those who were pregnant and patients with pre-existing chronic pain were excluded from the study.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026